AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1798005 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure measurement
Number of subjects: 318
Study 1798005 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic (ECG) voltages
Number of subjects: 318
Study 6358278 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-spectrum sunlight exposure (1, 2, 3, 6, and 9 sunburn units, approximately 30-270 millijoules/cm2)
Number of subjects: 22
Study 6358278 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA radiation exposure
Number of subjects: 22
Study 6358278 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemal dose of UVB or UVA radiation
Number of subjects: 22
Study 6358278 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanin sun protection factor values
Number of subjects: 22
Study 31601583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (24 sessions of real acupuncture)
Number of subjects: 60
Study 31601583 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (24 sessions using a placebo needle)
Number of subjects: 60
Study 31601583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 60
Study 31601583 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (IV; 0.01-100 mg)
Number of subjects: 180
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (SC; 6.25 mg every 2 weeks, 12.5 mg weekly, 37.5 mg weekly)
Number of subjects: 180
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (IV doses ≥9 mg)
Number of subjects: 180
Study 27402064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV and SC)
Number of subjects: 180
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (SAD)
Number of subjects: 180
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (MAD)
Number of subjects: 180
Study 27402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulizumab pegol (IV or SC)
Number of subjects: 180
Study 25439501 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Lifestyle Intervention Prescription (FLIP)
Number of subjects: 59
Study 25015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline circulating total dpMGP level
Number of subjects: 215
Study 25015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dpMGP level in younger patients (age < 57)
Number of subjects: 215
Study 25015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dpMGP level in older patients (age ≥ 57)
Number of subjects: 215
Study 25015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent correlates of dpMGP level
Number of subjects: 215
Study 22230419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischia thermal water nasal aerosol for 15 days per month for three consecutive months
Number of subjects: 40
Study 22230419 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (isotonic) solution
Number of subjects: 40
Study 19076192 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) peels
Number of subjects: 44
Study 19076192 — intervention group
Group type: COMPARATOR
Intervention: 20% salicylic-10% mandelic acid peels (SMPs)
Number of subjects: 44
Study 17560135 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive, Prime & Bond NT
Number of subjects: 40
Study 17560135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive, Xeno III
Number of subjects: 40
Study 15541411 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone followed by 400 microg oral misoprostol 2 days later
Number of subjects: 321
Study 15541411 — intervention group
Group type: EXPERIMENTAL
Intervention: Home use of misoprostol
Number of subjects: 321
Study 11468134 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg, i.m. injection every second week for 6 months)
Number of subjects: 281
Study 11468134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.m. injection every second week for 6 months)
Number of subjects: 281
Study 11468134 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 281
Study 9746115 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 infusion
Number of subjects: 10
Study 8312508 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted angioplasty
Number of subjects: 134
Study 8312508 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 134
Study 3170533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpastes (0.1 ppm F‐ as nicomethanolhydrofluoride, 1100 ppm F‐ as NaF, 1350 ppm F‐ as NaF/MFP)
Number of subjects: 10
Study 3170533 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (0.1 ppm F‐)
Number of subjects: 10
Study 31236002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 53
Study 31236002 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 53
Study 27786509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition at encoding, immediate retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition at encoding, 1-week delay retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: COMPARATOR
Intervention: Sober condition at encoding, immediate retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition at encoding, immediate retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition at encoding, 1-week delay retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated condition at encoding, immediate retrieval
Number of subjects: 249
Study 27786509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated condition at encoding, 1-week delay retrieval
Number of subjects: 249
Study 25860108 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced referral process including a wallet card and standardized physician monologue
Number of subjects: 202
Study 25860108 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced referral process (control group)
Number of subjects: 202
Study 24624849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.2-1.4 microg kg(‐1) per hour)
Number of subjects: 28
Study 24624849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 28
Study 21471823 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (0.625 mg conjugated estrogens)
Number of subjects: 51
Study 21471823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19585697 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating popliteal catheter (STIM group)
Number of subjects: 48
Study 19585697 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulating popliteal catheter (NONSTIM group)
Number of subjects: 48
Study 17364275 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid for 16 weeks
Number of subjects: 101
Study 17364275 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg bid from the first trimester throughout pregnancy
Number of subjects: 101
Study 17364275 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment in nonpregnant women
Number of subjects: 101
Study 17364275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 15295655 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose eyedrops
Number of subjects: 36
Study 15295655 — intervention group
Group type: COMPARATOR
Intervention: Commercially available eyedrops (hyaluronan or hydroxyethylcellulose)
Number of subjects: 36
Study 12216603 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Acupuncture
Number of subjects: 24
Study 12216603 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (mock-TENS)
Number of subjects: 24
Study 10502902 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sessions (orthodontic pain induced by placing orthodontic separators)
Number of subjects: 14
Study 10502902 — intervention group
Group type: COMPARATOR
Intervention: Control sessions
Number of subjects: 14
Study 7768078 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.3 mg or 1.0 mg)
Number of subjects: 0
Study 7768078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2322788 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast barium enema
Number of subjects: 625
Study 2322788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible rectosigmoidoscopy
Number of subjects: 625
Study 2322788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methods (double contrast barium enema and flexible rectosigmoidoscopy)
Number of subjects: 625
Study 2322788 — intervention group
Group type: COMPARATOR
Intervention: Control group (negative assessment)
Number of subjects: 625
Study 232147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m pyrophosphate (PPi)
Number of subjects: 24
Study 232147 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m methylene diphosphonate (MDP)
Number of subjects: 24
Study 232147 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of relative intensity with each agent
Number of subjects: 24
Study 29959852 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric protein module added to enteral nutrition (EN) to reach protein goal by day 4
Number of subjects: 25
Study 29959852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligomeric protein supplementation
Number of subjects: 25
Study 29959852 — intervention group
Group type: COMPARATOR
Intervention: Routine enteral nutrition (control)
Number of subjects: 25
Study 28091703 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.1, 0.2, and 0.3 mg/kg BW)
Number of subjects: 12
Study 28091703 — intervention group
Group type: COMPARATOR
Intervention: Esmolol (0.5, 1, and 1.5 mg/kg BW)
Number of subjects: 12
Study 28091703 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol and Esmolol
Number of subjects: 12
Study 26560483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.65 mg
Number of subjects: 49
Study 26560483 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone
Number of subjects: 49
Study 23726977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 24
Study 23726977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21346734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide adjunctive treatment
Number of subjects: 53
Study 21346734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19564531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrecurrence therapy for early stage colon cancer
Number of subjects: 537
Study 19564531 — intervention group
Group type: COMPARATOR
Intervention: Postrecurrence therapy for late stage colon cancer
Number of subjects: 537
Study 19564531 — intervention group
Group type: EXPERIMENTAL
Intervention: First detection methods for recurrence in early stage colon cancer
Number of subjects: 537
Study 19564531 — intervention group
Group type: COMPARATOR
Intervention: First detection methods for recurrence in late stage colon cancer
Number of subjects: 537
Study 19564531 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival after second surgery after recurrence for early stage
Number of subjects: 537
Study 19564531 — intervention group
Group type: COMPARATOR
Intervention: Median survival after second surgery after recurrence for late stage
Number of subjects: 537
Study 19564531 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence patterns for early stage colon cancer
Number of subjects: 537
Study 19564531 — intervention group
Group type: COMPARATOR
Intervention: Recurrence patterns for late stage colon cancer
Number of subjects: 537
Study 17530377 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication of pain site by finger
Number of subjects: 137
Study 17530377 — intervention group
Group type: COMPARATOR
Intervention: Indication of pain site by hand
Number of subjects: 137
Study 15189478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 45
Study 15189478 — intervention group
Group type: COMPARATOR
Intervention: Weight training (WT)
Number of subjects: 45
Study 15189478 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (NT)
Number of subjects: 45
Study 11816439 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine-Clindamycin (QC7)
Number of subjects: 129
Study 11816439 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (A7)
Number of subjects: 129
Study 9501680 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR-A group
Number of subjects: 73
Study 9501680 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR group
Number of subjects: 73
Study 9501680 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 73
Study 8472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow (PEF)
Number of subjects: 150
Study 8472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute decrease in PEF of > or = 70 l.min‐1
Number of subjects: 150
Study 8472058 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute decrease in PEF of > or = 80 l.min‐1
Number of subjects: 150
Study 8472058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF readings
Number of subjects: 150
Study 3511209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week benzathine penicillin G injections
Number of subjects: 179
Study 3511209 — intervention group
Group type: COMPARATOR
Intervention: 4-week benzathine penicillin G injections
Number of subjects: 179
Study 31690523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent vacuum therapy (IVT) at -50 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.
Number of subjects: 70
Study 31690523 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment at -5 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.
Number of subjects: 70
Study 31138279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 48
Study 31138279 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 48
Study 28029852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based weight-loss intervention (n=100)
Number of subjects: 194
Study 28029852 — intervention group
Group type: COMPARATOR
Intervention: Control group (Progressive Muscle Relaxation, n=94)
Number of subjects: 194
Study 26292675 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeLab intervention (includes professional development for teachers, preparatory lessons, hands-on practical day at LifeLab, 'Meet the Scientist' session, post-visit lessons, participation in LifeLab Schools' Conference)
Number of subjects: 2500
Study 26292675 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools not receiving the LifeLab intervention)
Number of subjects: 2500
Study 24107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Healthy Living Program (environmental intervention)
Number of subjects: 180
Study 24107083 — intervention group
Group type: EXPERIMENTAL
Intervention: Community assessments in intervention trial communities
Number of subjects: 180
Study 24107083 — intervention group
Group type: COMPARATOR
Intervention: Prevalence survey measurements
Number of subjects: 180
Study 21866660 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS group
Number of subjects: 180
Study 21866660 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-PSS group
Number of subjects: 180
Study 21866660 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS group and Non-PSS group
Number of subjects: 180
Study 19712709 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NF), combined protocol of theta/beta training and slow cortical potentials (SCP) training, 18 units of 50 minutes each
Number of subjects: 72
Study 19712709 — intervention group
Group type: COMPARATOR
Intervention: Control training (computerized attention skills training)
Number of subjects: 72
Study 18218206 — intervention group
Group type: EXPERIMENTAL
Intervention: External positive end-expiratory pressure (PEEPe) at 80% of intrinsic PEEP (PEEPi)
Number of subjects: 15
Study 18218206 — intervention group
Group type: EXPERIMENTAL
Intervention: External positive end-expiratory pressure (PEEPe) at 100% of intrinsic PEEP (PEEPi)
Number of subjects: 15
Study 18218206 — intervention group
Group type: EXPERIMENTAL
Intervention: External positive end-expiratory pressure (PEEPe) at 120% of intrinsic PEEP (PEEPi)
Number of subjects: 15
Study 18218206 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in plateau pressure (Pplat) at different PEEPe levels
Number of subjects: 15
Study 14688163 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU rFSH
Number of subjects: 257
Study 14688163 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU rFSH
Number of subjects: 257
Study 11341128 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 29
Study 11341128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9136820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure of Helicobacter pylori infection
Number of subjects: 460
Study 9136820 — intervention group
Group type: COMPARATOR
Intervention: Persisting Helicobacter pylori infection
Number of subjects: 460
Study 8489087 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin admixed with clindamycin 900 mg IVPB every 8 hours (Group I n = 80)
Number of subjects: 126
Study 8489087 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin IVPB q8h plus clindamycin 600 mg IVPB every 6 hours (Group II n = 46)
Number of subjects: 126
Study 3328790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 160 (H 16)
Number of subjects: 20
Study 3328790 — intervention group
Group type: COMPARATOR
Intervention: Sodium Meglumine diatrizoate (R 76)
Number of subjects: 20
Study 2674460 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of cisplatin (CDDP)/m2
Number of subjects: 103
Study 2674460 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of carboplatin (CBDCA)/m2
Number of subjects: 103
Study 31122824 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (Moviprep® after capsule arrival)
Number of subjects: 101
Study 31122824 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (Clear liquids diet + fasting)
Number of subjects: 101
Study 31122824 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (Protocol A + Moviprep® before examination)
Number of subjects: 101
Study 28735826 — intervention group
Group type: EXPERIMENTAL
Intervention: affron® 28mg/day
Number of subjects: 128
Study 28735826 — intervention group
Group type: EXPERIMENTAL
Intervention: affron® 22mg/day
Number of subjects: 128
Study 28735826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 25934131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1320 mg/day of EPA and 880 mg/day of DHA
Number of subjects: 82
Study 25934131 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 82
Study 23438159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone (PAL)
Number of subjects: 27
Study 23438159 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 27
Study 21962261 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI at 1 hour
Number of subjects: 28
Study 21962261 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI at 24 hours
Number of subjects: 28
Study 21962261 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB at 24 hours
Number of subjects: 28
Study 21962261 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 at 1 hour
Number of subjects: 28
Study 21962261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor‐α at 1 hour
Number of subjects: 28
Study 19101265 — intervention group
Group type: EXPERIMENTAL
Intervention: rSo(2) desaturation score greater than 3,000%‐second
Number of subjects: 0
Study 17050790 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg once daily for 14 days
Number of subjects: 24
Study 17050790 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for 14 days
Number of subjects: 24
Study 17050790 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg once daily for 14 days
Number of subjects: 24
Study 17050790 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo once daily for 14 days
Number of subjects: 24
Study 15327932 — intervention group
Group type: EXPERIMENTAL
Intervention: Social attention allocation using eye gaze cues
Number of subjects: 1
Study 15327932 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic cues (words) for attention allocation
Number of subjects: 1
Study 15327932 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic allocation of attention
Number of subjects: 1
Study 10906619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 10906619 — intervention group
Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 0
Study 9565715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 14
Study 9565715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8401679 — intervention group
Group type: EXPERIMENTAL
Intervention: Systen
Number of subjects: 104
Study 8401679 — intervention group
Group type: COMPARATOR
Intervention: Estraderm
Number of subjects: 104
Study 8401679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 2877955 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 12
Study 2877955 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 12
Study 31853864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile Reflux Scintigraphy (BRS)
Number of subjects: 40
Study 31853864 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Endoscopy (UGE)
Number of subjects: 40
Study 31853864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile Reflux Scintigraphy (BRS) and UGE findings
Number of subjects: 40
Study 29072677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 24